[1] XU Y,GU B,HUANG M,et al.Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia[J].J Thorac Dis,2015,7(3):376-385. [2] 全国细菌耐药监测网.全国细菌耐药监测网2014—2019年细菌耐药性监测报告[J].中国感染控制杂志,2021,20(1):15-30. [3] BAR-YOSEPH H,COHEN N,KORYTNY A,et al.Risk factors for mortality among carbapenem-resistant Enterobacteriaceae carriers with focus on immunosuppression[J].J Infect,2019,78(2):101-105. [4] KUMUDUNIE W G M,WIJESOORIYA L I,NAMALIE K D,et al.Epidemiology of multidrug-resistant Enterobacteriaceae in Sri Lanka: First evidence of blaKPC harboring Klebsiella pneumoniae[J].J Infect Public Health,2020,13(9):1330-1335. [5] 谢强,谢瑞玉,曹明杰,等.2012—2016年某三甲医院5种重要临床分离菌的耐药性监测[J].临床输血与检验,2020,22(2):190-194. [6] Clinical and Laboratory Standards Institute (CLSI) .Performance standards for Antimicrobial susceptibility testing[S].M100-S29, 2019. [7] TACCONELLI E,MAZZAFERRI F,DE SMET A M,et al.ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers[J].Clin Microbiol Infect,2019,25(7): 807-817. [8] TZOUVELEKIS L S,MARKOGIANNAKIS A,PSICHOGIOU M,et al.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions[J].Clin Microbiol Rev,2012,25(4):682-707. [9] 喻华,徐雪松,李敏,等.肠杆菌目细菌碳青霉烯酶的实验室检测和临床报告规范专家共识[J].中国感染与化疗杂志,2020,20(6):671-680. [10] 王方,吴新明,王彦,等.ERIC-PCR技术与MLST技术对30株耐碳青霉烯类肺炎克雷伯菌的基因分型结果观察[J].山东医药,2020,60(30):35-39. [11] 杨燕文,吴梦莹,韩鹏鹏,等.耐碳青霉烯类肺炎克雷伯菌耐药性及耐药基因的研究[J].中国医学装备,2020,17(1):118-121. [12] 徐淑晔,郭政新.碳青霉烯类肺炎克雷伯菌耐药基因型分析[J].淮海医药,2020,38(3):302-305. [13] FALAGAS M E,MARAKI S,KARAGEORGOPOULOS D E,et al.Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin[J].Int J Antimicrob Agents,2010,35(3):240-243. [14] JIANG Y,SHEN P,WEI Z Q,et al.Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China[J].Int J Antimicrob Agents,2015,45(1):66-70. [15] DEMIR T,BUYUKGUCLU T.Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community-and hospital-acquired urinary tract infections in Turkey[J].Int J Infect Dis,2013,17(11):e966-e970. [16] ENDIMIANI A,PATEL G,HUJER K M,et al.In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates,including those nonsusceptible to tigecycline and/or colistin[J].Antimicrob Agents Chemother,2010,54(1):526-529. [17] 丁月平,陆军,李曦,等.基于全基因组测序对碳青霉烯类耐药肺炎克雷伯菌的耐药基因分析[J].中华临床感染病杂志,2019,12(2):122-126. [18] POURNARAS S,KOUMAKI V,SPANAKIS N,et al.Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance[J].Int J Antimicrob Agents,2016,48(1):11-18. |